[144] Takeda Pharmaceutical Company Limited American SEC Filing
Takeda Pharmaceutical Company Limited (NYSE: TAK) filed a Form 144 indicating the proposed sale of 169,313 American Depositary Shares (ADSs). The securities were acquired via restricted stock unit (RSU) awards that vested on 07/01/2025 and have an aggregate market value of US$2,610,806.46. The filer plans to sell the shares through Interactive Brokers LLC on or about 07/09/2025. According to the notice, the issuer has 123,490,548 ADSs outstanding, and the planned sale will be executed on the NYSE.
Form 144 is a disclosure of intent, not a confirmation that the sale has occurred. The filing contains no indication of undisclosed adverse information, and no other sales by the filer were reported in the past three months. No financial performance metrics or strategic updates were provided; the document is strictly related to the planned disposition of shares.
Takeda Pharmaceutical Company Limited (NYSE: TAK) ha presentato un Modulo 144 indicando la proposta vendita di 169.313 American Depositary Shares (ADS). I titoli sono stati acquisiti tramite assegnazioni di unit脿 azionarie vincolate (RSU) maturate il 01/07/2025 e hanno un valore di mercato complessivo di 2.610.806,46 USD. Il presentatore intende vendere le azioni tramite Interactive Brokers LLC intorno al 09/07/2025. Secondo l鈥檃vviso, l鈥檈mittente ha 123.490.548 ADS in circolazione e la vendita pianificata sar脿 eseguita sul NYSE.
Il Modulo 144 猫 una comunicazione di intenti, non una conferma che la vendita sia avvenuta. La dichiarazione non indica informazioni negative non divulgate e non sono state segnalate altre vendite da parte del presentatore negli ultimi tre mesi. Non sono stati forniti dati finanziari o aggiornamenti strategici; il documento riguarda esclusivamente la prevista cessione delle azioni.
Takeda Pharmaceutical Company Limited (NYSE: TAK) present贸 un Formulario 144 indicando la propuesta de venta de 169,313 American Depositary Shares (ADS). Los valores fueron adquiridos mediante premios de unidades de acciones restringidas (RSU) que se consolidaron el 01/07/2025 y tienen un valor de mercado agregado de 2,610,806.46 USD. El declarante planea vender las acciones a trav茅s de Interactive Brokers LLC alrededor del 09/07/2025. Seg煤n el aviso, el emisor tiene 123,490,548 ADS en circulaci贸n y la venta planificada se ejecutar谩 en el NYSE.
El Formulario 144 es una divulgaci贸n de intenci贸n, no una confirmaci贸n de que la venta haya ocurrido. La presentaci贸n no contiene indicios de informaci贸n adversa no revelada, y no se reportaron otras ventas por parte del declarante en los 煤ltimos tres meses. No se proporcionaron m茅tricas financieras ni actualizaciones estrat茅gicas; el documento est谩 estrictamente relacionado con la disposici贸n planeada de las acciones.
Takeda Pharmaceutical Company Limited (NYSE: TAK)電� Form 144毳� 鞝滌稖頃橃棳 169,313臧滌潣 American Depositary Shares (ADSs) 韺愲Г 瓿勴殟鞚� 鞎岆牳鞀惦媹雼�. 鞚� 歃濌秾霌れ潃 2025雲� 7鞗� 1鞚检棎 甓岆Μ臧� 頇曥爼霅� 鞝滍暅欤检嫕雼渼(RSU) 氤挫儊鞙茧 旆摑霅橃棃鞙茧┌, 齑� 鞁滌灔 臧�旃橂姅 2,610,806.46 氙戈淡 雼煬鞛呺媹雼�. 鞝滌稖鞛愲姅 Interactive Brokers LLC毳� 韱淀暣 2025雲� 7鞗� 9鞚缄步 欤检嫕鞚� 毵る弰頃� 瓿勴殟鞛呺媹雼�. 瓿店碃鞐� 霐半ゴ氅�, 氚滍枆靷姅 123,490,548 ADS臧� 氚滍枆霅橃柎 鞛堨溂氅� 鞓堨爼霅� 毵る弰電� NYSE鞐愳劀 鞚措（鞏挫 鞓堨爼鞛呺媹雼�.
Form 144電� 毵る弰 鞚橃偓 瓿店皽鞚� 肟�, 毵る弰 鞕勲毳� 鞚橂頃橃 鞎婌姷雼堧嫟. 鞝滌稖靹滌棎電� 瓿店皽霅橃 鞎婌潃 攵�鞝曥爜 鞝曤炒臧� 鞐嗢溂氅�, 鞝滌稖鞛愱皜 歆�雮� 3臧滌洈臧� 雼るジ 毵る弰毳� 氤搓碃頃� 氚� 鞐嗢姷雼堧嫟. 鞛 靹标臣 歆�響滊倶 鞝勲灥鞝� 鞐呺嵃鞚错姼電� 鞝滉车霅橃 鞎婌晿鞙茧┌, 氍胳劀電� 欤检嫕 毵る弰 瓿勴殟瓿� 甏�霠悳 雮挫毄鞐� 頃滌爼霅╇媹雼�.
Takeda Pharmaceutical Company Limited (NYSE : TAK) a d茅pos茅 un formulaire 144 indiquant la vente propos茅e de 169 313 American Depositary Shares (ADS). Les titres ont 茅t茅 acquis via des attributions d鈥檜nit茅s d鈥檃ctions restreintes (RSU) qui ont acquis leurs droits le 01/07/2025 et ont une valeur marchande totale de 2 610 806,46 USD. Le d茅clarant pr茅voit de vendre les actions par l鈥檌nterm茅diaire de Interactive Brokers LLC aux alentours du 09/07/2025. Selon l鈥檃vis, l鈥櫭﹎etteur a 123 490 548 ADS en circulation, et la vente pr茅vue sera ex茅cut茅e sur le NYSE.
Le formulaire 144 est une d茅claration d鈥檌ntention, et non une confirmation que la vente a eu lieu. Le d茅p么t ne contient aucune indication d鈥檌nformations d茅favorables non divulgu茅es, et aucune autre vente par le d茅clarant n鈥檃 茅t茅 signal茅e au cours des trois derniers mois. Aucun indicateur de performance financi猫re ni mise 脿 jour strat茅gique n鈥檃 茅t茅 fourni ; le document concerne strictement la cession pr茅vue des actions.
Takeda Pharmaceutical Company Limited (NYSE: TAK) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 169.313 American Depositary Shares (ADS) anzeigt. Die Wertpapiere wurden durch Restricted Stock Unit (RSU)-Awards, die am 01.07.2025 f盲llig wurden, erworben und haben einen Gesamtmarktwert von 2.610.806,46 US-Dollar. Der Einreicher plant, die Aktien 眉ber Interactive Brokers LLC am oder um den 09.07.2025 zu verkaufen. Laut der Mitteilung hat der Emittent 123.490.548 ausstehende ADS, und der geplante Verkauf wird an der NYSE 诲耻谤肠丑驳别蹿眉丑谤迟.
Formular 144 ist eine Absichtserkl盲rung, keine Best盲tigung, dass der Verkauf stattgefunden hat. Die Einreichung enth盲lt keine Hinweise auf nicht offengelegte negative Informationen, und in den letzten drei Monaten wurden keine weiteren Verk盲ufe des Einreichers gemeldet. Es wurden keine finanziellen Leistungskennzahlen oder strategischen Updates bereitgestellt; das Dokument bezieht sich ausschlie脽lich auf die geplante Ver盲u脽erung der Aktien.
- None.
- Insider plans to sell 169,313 ADSs valued at US$2.6 million, which some investors may interpret as a modestly negative sentiment signal despite representing only about 0.14% of shares outstanding.
Insights
TL;DR: 169,313-share Form 144 equals ~US$2.6 M; small vs 123 M ADS float, neutral liquidity event.
The filing signals an insider鈥檚 intention to monetize equity compensation valued at roughly US$2.6 million. Against the 123.5 million ADSs outstanding, the stake represents about 0.14%, a level unlikely to exert material market pressure. Because Form 144 is a notice, execution risk remains, and the sale may occur under pre-existing 10b5-1 instructions. Absent accompanying operational data or earnings commentary, the event is best viewed as routine insider diversification rather than a directional indicator for TAK鈥檚 fundamentals.
TL;DR: Routine RSU-driven insider sale; governance impact minimal, disclosure aligns with Rule 144 requirements.
The shares originate from recently-vested RSUs, suggesting ordinary compensation liquidity rather than strategic divestiture. The filer affirms no knowledge of undisclosed adverse information, satisfying Rule 144 anti-fraud safeguards. No aggregation of prior sales was necessary, indicating limited ongoing disposition activity. From a governance perspective, transparent advance notice and broker-facilitated execution on the NYSE meet best-practice standards. Overall, the event poses negligible governance risk.
Takeda Pharmaceutical Company Limited (NYSE: TAK) ha presentato un Modulo 144 indicando la proposta vendita di 169.313 American Depositary Shares (ADS). I titoli sono stati acquisiti tramite assegnazioni di unit脿 azionarie vincolate (RSU) maturate il 01/07/2025 e hanno un valore di mercato complessivo di 2.610.806,46 USD. Il presentatore intende vendere le azioni tramite Interactive Brokers LLC intorno al 09/07/2025. Secondo l鈥檃vviso, l鈥檈mittente ha 123.490.548 ADS in circolazione e la vendita pianificata sar脿 eseguita sul NYSE.
Il Modulo 144 猫 una comunicazione di intenti, non una conferma che la vendita sia avvenuta. La dichiarazione non indica informazioni negative non divulgate e non sono state segnalate altre vendite da parte del presentatore negli ultimi tre mesi. Non sono stati forniti dati finanziari o aggiornamenti strategici; il documento riguarda esclusivamente la prevista cessione delle azioni.
Takeda Pharmaceutical Company Limited (NYSE: TAK) present贸 un Formulario 144 indicando la propuesta de venta de 169,313 American Depositary Shares (ADS). Los valores fueron adquiridos mediante premios de unidades de acciones restringidas (RSU) que se consolidaron el 01/07/2025 y tienen un valor de mercado agregado de 2,610,806.46 USD. El declarante planea vender las acciones a trav茅s de Interactive Brokers LLC alrededor del 09/07/2025. Seg煤n el aviso, el emisor tiene 123,490,548 ADS en circulaci贸n y la venta planificada se ejecutar谩 en el NYSE.
El Formulario 144 es una divulgaci贸n de intenci贸n, no una confirmaci贸n de que la venta haya ocurrido. La presentaci贸n no contiene indicios de informaci贸n adversa no revelada, y no se reportaron otras ventas por parte del declarante en los 煤ltimos tres meses. No se proporcionaron m茅tricas financieras ni actualizaciones estrat茅gicas; el documento est谩 estrictamente relacionado con la disposici贸n planeada de las acciones.
Takeda Pharmaceutical Company Limited (NYSE: TAK)電� Form 144毳� 鞝滌稖頃橃棳 169,313臧滌潣 American Depositary Shares (ADSs) 韺愲Г 瓿勴殟鞚� 鞎岆牳鞀惦媹雼�. 鞚� 歃濌秾霌れ潃 2025雲� 7鞗� 1鞚检棎 甓岆Μ臧� 頇曥爼霅� 鞝滍暅欤检嫕雼渼(RSU) 氤挫儊鞙茧 旆摑霅橃棃鞙茧┌, 齑� 鞁滌灔 臧�旃橂姅 2,610,806.46 氙戈淡 雼煬鞛呺媹雼�. 鞝滌稖鞛愲姅 Interactive Brokers LLC毳� 韱淀暣 2025雲� 7鞗� 9鞚缄步 欤检嫕鞚� 毵る弰頃� 瓿勴殟鞛呺媹雼�. 瓿店碃鞐� 霐半ゴ氅�, 氚滍枆靷姅 123,490,548 ADS臧� 氚滍枆霅橃柎 鞛堨溂氅� 鞓堨爼霅� 毵る弰電� NYSE鞐愳劀 鞚措（鞏挫 鞓堨爼鞛呺媹雼�.
Form 144電� 毵る弰 鞚橃偓 瓿店皽鞚� 肟�, 毵る弰 鞕勲毳� 鞚橂頃橃 鞎婌姷雼堧嫟. 鞝滌稖靹滌棎電� 瓿店皽霅橃 鞎婌潃 攵�鞝曥爜 鞝曤炒臧� 鞐嗢溂氅�, 鞝滌稖鞛愱皜 歆�雮� 3臧滌洈臧� 雼るジ 毵る弰毳� 氤搓碃頃� 氚� 鞐嗢姷雼堧嫟. 鞛 靹标臣 歆�響滊倶 鞝勲灥鞝� 鞐呺嵃鞚错姼電� 鞝滉车霅橃 鞎婌晿鞙茧┌, 氍胳劀電� 欤检嫕 毵る弰 瓿勴殟瓿� 甏�霠悳 雮挫毄鞐� 頃滌爼霅╇媹雼�.
Takeda Pharmaceutical Company Limited (NYSE : TAK) a d茅pos茅 un formulaire 144 indiquant la vente propos茅e de 169 313 American Depositary Shares (ADS). Les titres ont 茅t茅 acquis via des attributions d鈥檜nit茅s d鈥檃ctions restreintes (RSU) qui ont acquis leurs droits le 01/07/2025 et ont une valeur marchande totale de 2 610 806,46 USD. Le d茅clarant pr茅voit de vendre les actions par l鈥檌nterm茅diaire de Interactive Brokers LLC aux alentours du 09/07/2025. Selon l鈥檃vis, l鈥櫭﹎etteur a 123 490 548 ADS en circulation, et la vente pr茅vue sera ex茅cut茅e sur le NYSE.
Le formulaire 144 est une d茅claration d鈥檌ntention, et non une confirmation que la vente a eu lieu. Le d茅p么t ne contient aucune indication d鈥檌nformations d茅favorables non divulgu茅es, et aucune autre vente par le d茅clarant n鈥檃 茅t茅 signal茅e au cours des trois derniers mois. Aucun indicateur de performance financi猫re ni mise 脿 jour strat茅gique n鈥檃 茅t茅 fourni ; le document concerne strictement la cession pr茅vue des actions.
Takeda Pharmaceutical Company Limited (NYSE: TAK) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 169.313 American Depositary Shares (ADS) anzeigt. Die Wertpapiere wurden durch Restricted Stock Unit (RSU)-Awards, die am 01.07.2025 f盲llig wurden, erworben und haben einen Gesamtmarktwert von 2.610.806,46 US-Dollar. Der Einreicher plant, die Aktien 眉ber Interactive Brokers LLC am oder um den 09.07.2025 zu verkaufen. Laut der Mitteilung hat der Emittent 123.490.548 ausstehende ADS, und der geplante Verkauf wird an der NYSE 诲耻谤肠丑驳别蹿眉丑谤迟.
Formular 144 ist eine Absichtserkl盲rung, keine Best盲tigung, dass der Verkauf stattgefunden hat. Die Einreichung enth盲lt keine Hinweise auf nicht offengelegte negative Informationen, und in den letzten drei Monaten wurden keine weiteren Verk盲ufe des Einreichers gemeldet. Es wurden keine finanziellen Leistungskennzahlen oder strategischen Updates bereitgestellt; das Dokument bezieht sich ausschlie脽lich auf die geplante Ver盲u脽erung der Aktien.
FAQ
How many Takeda (TAK) ADSs are covered by the Form 144 filing?
What is the aggregate market value of the shares to be sold?
When is the approximate sale date for the Takeda ADSs?
On which exchange will the ADSs be sold?
How were the Takeda ADSs acquired by the filer?
Who is the broker handling the proposed sale?
How many Takeda ADSs are outstanding according to the filing?
